Aidan Burrell

Aidan Burrell

Auto-generated profile, based on publicly available information

Aidan Burrell

Intensive Care Medicine (A.B.), The Alfred Hospital, Melbourne, VIC, Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2020 in Medical Journal of Australia
Verified
Journal Article
Open access
PDF file
ABAidan Jc Burrell
Aidan Jc Burrell
BPBreanna Pellegrini
Breanna Pellegrini
FSFarhad Salimi
Farhad Salimi
HBHusna Begum
Husna Begum
TBTessa Broadley
Tessa Broadley
AUAndrew A Udy
Andrew A Udy
Objectives To describe the characteristics and outcomes of patients with COVID‐19 admitted to intensive care units (ICUs) during the initial months of the pandemic in Australia. Design, setting Pr...

6 May 2023 in Burns
Verified
Journal Article
Closed access
David GreenhalghDavid Greenhalgh
David Greenhalgh
DHDavid M. Hill
David M. Hill
DBDavid M. Burmeister
David M. Burmeister
EGEduardo I. Gus
Eduardo I. Gus
Heather ClelandHeather Cleland
Heather Cleland
RCRobert Cartotto
Robert Cartotto

20 April 2022 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
MWMarina Wainstein
Marina Wainstein
SMSamual MacDonald
Samual MacDonald
DFDaniel Fryer
Daniel Fryer
KYKyle Young
Kyle Young
VBValeria Balan
Valeria Balan
TGthe ISARIC Clinical Characterisation Group
the ISARIC Clinical Characterisation Group
Background: Acute kidney injury (AKI) is one of the most common and significant problems in patients with Coronavirus Disease 2019 (COVID-19). However, little is known about the incidence and impact of AKI occurring in the community or early in the hospital admission. The traditional Kidney Disease Improving Global Outcomes (KDIGO) definition can fail to identify patients for whom hospitalisation coincides with recovery of AKI as manifested by a decrease in serum creatinine (sCr). We hypothesised that an extended KDIGO (eKDIGO) definition, adapted from the International Society of Nephrology (ISN) 0by25 studies, would identify more cases of AKI in patients with COVID-19 and that these may correspond to community-acquired AKI (CA-AKI) with similarly poor outcomes as previously reported in this population. Methods and findings: All individuals recruited using the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC)–World Health Organization (WHO) Clinical Characterisation Protocol (CCP) and admitted to 1,609 hospitals in 54 countries with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection from February 15, 2020 to February 1, 2021 were included in the study. Data were collected and analysed for the duration of a patient’s admission. Incidence, staging, and timing of AKI were evaluated using a traditional and eKDIGO definition, which incorporated a commensurate decrease in sCr. Patients within eKDIGO diagnosed with AKI by a decrease in sCr were labelled as deKDIGO. Clinical characteristics and outcomes—intensive care unit (ICU) admission, invasive mechanical ventilation, and in-hospital death—were compared for all 3 groups of patients. The relationship between eKDIGO AKI and in-hospital death was assessed using survival curves and logistic regression, adjusting for disease severity and AKI susceptibility. A total of 75,670 patients were included in the final analysis cohort. Median length of admission was 12 days (interquartile range [IQR] 7, 20). There were twice as many patients with AKI identified by eKDIGO than KDIGO (31.7% versus 16.8%). Those in the eKDIGO group had a greater proportion of stage 1 AKI (58% versus 36% in KDIGO patients). Peak AKI occurred early in the admission more frequently among eKDIGO than KDIGO patients. Compared to those without AKI, patients in the eKDIGO group had worse renal function on admission, more in-hospital complications, higher rates of ICU admission (54% versus 23%) invasive ventilation (45% versus 15%), and increased mortality (38% versus 19%). Patients in the eKDIGO group had a higher risk of in-hospital death than those without AKI (adjusted odds ratio: 1.78, 95% confidence interval: 1.71 to 1.80, p-value < 0.001). Mortality and rate of ICU admission were lower among deKDIGO than KDIGO patients (25% versus 50% death and 35% versus 70% ICU admission) but significantly higher when compared to patients with no AKI (25% versus 19% death and 35% versus 23% ICU admission) (all p-values <5 × 10−5). Limitations include ad hoc sCr sampling, exclusion of patients with less than two sCr measurements, and limited availability of sCr measurements prior to initiation of acute dialysis. Conclusions: An extended KDIGO definition of AKI resulted in a significantly higher detection rate in this population. These additional cases of AKI occurred early in the hospital admission and were associated with worse outcomes compared to patients without AKI.


1 September 2020 in Australian Critical Care
Verified
Journal Article
Closed access
LCLee-anne S Chapple
Lee-anne S Chapple
KFKate Fetterplace
Kate Fetterplace
VAVarsha Asrani
Varsha Asrani
ABAidan Burrell
Aidan Burrell
ACAllen C. Cheng
Allen C. Cheng
EREmma Ridley
Emma Ridley

9 June 2022 in Medical Journal of Australia
Verified
Journal Article
Open access
HBHusna Begum
Husna Begum
ANAry S Neto
Ary S Neto
PAPatricia Alliegro
Patricia Alliegro
TBTessa Broadley
Tessa Broadley
TTTony Trapani
Tony Trapani
ABAidan Burrell
Aidan Burrell
To compare the demographic and clinical features, management, and outcomes for patients admitted with COVID‐19 to intensive care units (ICUs) during the first, second, and third waves of the pandemic in Australia. People aged 16 years or more admitted with polymerase chain reaction‐confirmed COVID‐19 to the 78 Australian ICUs participating in the Short Period Incidence Study of Severe Acute Respiratory Infection (SPRINT‐SARI) Australia project during the first (27 February – 30 June 2020), second (1 July 2020 – 25 June 2021), and third COVID‐19 waves (26 June – 1 November 2021). Primary outcome: in‐hospital mortality. Secondary outcomes: ICU mortality; ICU and hospital lengths of stay; supportive and disease‐specific therapies. 2493 people (1535 men, 62%) were admitted to 59 ICUs: 214 during the first (9%), 296 during the second (12%), and 1983 during the third wave (80%). The median age was 64 (IQR, 54–72) years during the first wave, 58 (IQR, 49–68) years during the second, and 54 (IQR, 41–65) years during the third. The proportion without co‐existing illnesses was largest during the third wave (41%; first wave, 32%; second wave, 29%). The proportion of ICU beds occupied by patients with COVID‐19 was 2.8% (95% CI, 2.7–2.9%) during the first, 4.6% (95% CI, 4.3–5.1%) during the second, and 19.1% (95% CI, 17.9–20.2%) during the third wave. Non‐invasive (42% v 15%) and prone ventilation strategies (63% v 15%) were used more frequently during the third wave than during the first two waves. Thirty patients (14%) died in hospital during the first wave, 35 (12%) during the second, and 281 (17%) during the third. After adjusting for age, illness severity, and other covariates, the risk of in‐hospital mortality was similar for the first and second waves, but 9.60 (95% CI, 3.52–16.7) percentage points higher during the third than the first wave. The demographic characteristics of patients in intensive care with COVID‐19 and the treatments they received during the third pandemic wave differed from those of the first two waves. Adjusted in‐hospital mortality was highest during the third wave.